KRAS and atrial fibrillation: KRAS2 and KRAS2–4/NRAS2–4/BRAF15 mut at >1000×cov and >5% AF were 47.6% and 63.5%, respectively, consistent with that previously reported in the same MCRC cohort by our group using direct sequencing [9, 10], and in the range of reported 45–55% KRAS2 and 65.6% KRAS2–4/NRAS2–4/BRAF15 mut [3].